Daré Bioscience's Ovaprene® Shows Promising Interim Phase 3 Results, Reinforcing Hormone-Free Contraceptive Potential
Event summary
- Daré Bioscience reported positive interim Phase 3 results for Ovaprene®, its hormone-free intravaginal contraceptive, with a 9% pregnancy rate consistent with prior expectations.
- The Data Safety Monitoring Board (DSMB) recommended continuing the study without modification, marking the second positive review.
- Vaginal odor was the most common adverse event, but its occurrence decreased by 5% compared to the previous review.
- The company expects to complete enrollment sufficient to achieve at least 2,500 cycles of exposure in 2026.
The big picture
Daré Bioscience’s Ovaprene® represents a potential first-in-category hormone-free contraceptive, addressing a significant unmet need in women’s health. The positive interim results reinforce its differentiation in a market dominated by hormonal methods, positioning it as a potential disruptor if approved. The company’s focus on rigorous clinical trials and regulatory engagement underscores its strategic approach to closing gaps in women’s health care.
What we're watching
- Regulatory Pathway
- Whether the FDA will accept fewer than 250 subjects completing 13 menstrual cycles of use to evaluate Ovaprene’s safety profile.
- Market Differentiation
- How Ovaprene’s hormone-free, monthly intravaginal contraceptive positioning will compete against existing short-acting hormonal methods.
- Execution Risk
- The pace at which Daré Bioscience can complete enrollment and achieve the primary endpoint analysis.
Related topics